Problems of VirologyProblems of VirologyВопросы вирусологии0507-40882411-2097Central Research Institute for Epidemiology55810.36233/0507-4088-70REVIEWSОБЗОРЫThe role of antiviral therapy in the management of patients with liver cirrhosis associated with chronic HBV and HCV infectionРоль противовирусной терапии в лечении больных циррозом печени, ассоциированным с хронической HBV- и HCV-инфекциейhttps://orcid.org/0000-0001-9809-8015GarbuzenkoD. V.ГарбузенкоД. В.
Russian Federation

Dmitry V. Garbuzenko, D.Sci. (Med.), Professor of Department of Faculty Surgery

454092, Chelyabinsk, Russia

Гарбузенко Дмитрий Викторович, д-р мед. наук, профессор кафедры факультетской хирургии

454092, Челябинск, Россия

garb@inbox.ruFSBEI HE «South Ural State Medical University» of the Ministry of the Health of RussiaФГБОУ ВО «Южно-Уральский государственный медицинский университет» Минздрава России041120216653313390411202104112021Copyright ©; 2021, Garbuzenko D.V.Copyright ©; 2021, Гарбузенко Д.В.2021Garbuzenko D.V.Гарбузенко Д.В.https://creativecommons.org/licenses/by/4.0https://virusjour.crie.ru/jour/article/view/558

The formation of the liver cirrhosis (LC) is an unfavorable event of the natural history of chronic liver diseases being accompanied by complications that often cause a fatal outcome. The study of the effectiveness of drugs that affect various etiopathogenetic mechanisms of this condition is an urgent problem of modern hepatology.

The aim of the review was to show the role of antiviral therapy (AVT) in the management of patients with LC associated with chronic HBV (hepatitis B virus) and HCV (hepatitis C virus) infection.

PubMed database, Google Scholar search engine, Cochrane Systematic Reviews, eLIBRARY.RU electronic scientific library, as well as the reference lists of articles were used to search for scientific articles. The relevant objectives of the review of the publications were identified for the period since 2000 up to 2021 by the search queries as following: «liver cirrhosis», «liver fibrosis», «chronic HBV infection», «chronic HCV infection», «portal hypertension», «treatment». The inclusion criteria were restricted to the management of patients with LC associated with chronic HBV and HCV infection.

Current guidelines recommend indefinite treatment of patients with HBV-associated LC with nucleos(t)ide analogues regardless of serum HBV DNA levels, while the modern concept of using direct-acting antiviral drug combinations has become the standard treatment for HCV-associated cirrhosis. Studies have shown the ability of AVT to inhibit and reverse fibrotic processes in LC associated with chronic HBV and HCV infection. It has also been reported that HBV/HCV eradication prior to orthotopic liver transplantation improves long-term overall survival.

This, in turn, can reduce the severity of portal hypertension and decrease the risk of associated complications, as well as normalize liver function. Thus, ensuring the availability of drugs for those in need of AVT will not only help prevent the development of LC, but also improve the quality of life and increase its expectancy of patients suffering from this disease.

Формирование цирроза печени (ЦП) служит неблагоприятным событием естественного течения её хронических заболеваний и может сопровождаться осложнениями, которые нередко становятся причиной фатального исхода. Изучение эффективности лекарственных средств (ЛС), влияющих на различные этиопатогенетические механизмы этого состояния, представляет собой одну из актуальных проблем современной гепатологии. Цель обзора – показать роль противовирусной терапии (ПВТ) в лечении ЦП, ассоциированного с хронической инфекцией, вызываемой вирусами гепатитов В (hepatitis B virus, HBV) и С (hepatitis C virus, HCV).

Для поиска научных статей использовались база данных PubMed, поисковая система Google Scholar, Кокрейновские систематические обзоры, электронная научная библиотека eLIBRARY.RU, а также пристатейные списки литературы. В соответствии с задачами работы отбирались публикации за период 2000–2021 гг. по поисковым запросам: «цирроз печени»; «фиброз печени»; «хроническая HBV-инфекция»; «хроническая HCV-инфекция»; «портальная гипертензия»; «лечение». Критерии включения ограничивались проблемой терапии ЦП, ассоциированного с хронической HBV- и HCV-инфекцией.

Текущие гайдлайны рекомендуют бессрочное лечение пациентов с HBV-ассоциированным ЦП аналогами нуклеозидов/нуклеотидов (АН/Н) независимо от сывороточных уровней ДНК HBV; стандартом же терапии HСV-ассоциированного ЦП стала современная концепция использования комбинаций противовирусных препаратов прямого действия. Исследования показали способность ПВТ ингибировать и реверсировать фибротические процессы, что, в свою очередь, может уменьшить выраженность портальной гипертензии (ПГ) и снизить риск связанных с ней осложнений, а также нормализовать печёночную функцию. Кроме того, отмечается, что осуществление перед ортотопической трансплантацией печени (ОТП) эрадикации HBV/ HCV повышает общую выживаемость в долгосрочной перспективе. Таким образом, обеспечение доступности препаратов для нуждающихся в данных лечебных мероприятиях будет способствовать не только профилактике ЦП, но также позволит улучшить качество и увеличить продолжительность жизни страдающих им пациентов.

reviewliver cirrhosischronic HBV infectionchronic HCV infectionantiviral therapyобзорцирроз печенихроническая HBV-инфекцияхроническая HСV-инфекцияпротивовирусная терапия1. Jung Y.K., Yim H.J. Reversal of liver cirrhosis: current evidence and expectations. Korean J. Intern. Med. 2017; 32(2): 213–8. https://doi.org/10.3904/kjim.2016.2682. Feld J., Janssen H.L., Abbas Z., Elewaut A., Ferenci P., Isakov V., et al. Review Team. World Gastroenterology Organisation Global Guideline Hepatitis B: September 2015. J. Clin. Gastroenterol. 2016; 50(9): 691–703. https://doi.org/10.1097/MCG.00000000000006473. Cornberg M., Lok A.S., Terrault N.A., Zoulim F. 2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B – Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. J. Hepatol. 2020; 72(3): 539–57. https://doi.org/10.1002/hep.310304. Kim S.U., Park J.Y., Kim D.Y., Ahn S.H., Choi E.H., Seok J.Y., et al. Non-invasive assessment of changes in liver fibrosis via liver stiffness measurement in patients with chronic hepatitis B: impact of antiviral treatment on fibrosis regression. Hepatol. Int. 2010; 4(4): 673–80. https://doi.org/10.1007/s12072-010-9201-75. Liaw Y.F., Sung J.J., Chow W.C., Farrell G., Lee C.Z., Yuen H., et al., Cirrhosis Asian Lamivudine Multicentre Study Group. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. 2004; 351(15): 1521–31. https://doi.org/10.1056/NEJMoa0333646. Chang T.T., Liaw Y.F., Wu S.S., Schiff E., Han K.H., Lai C.L., et al. Long-term entecavir therapy results in the reversal of fibrosis/ cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010; 52(3): 886–93. https://doi.org/10.1002/hep.237857. Shin S.K., Kim J.H., Park H., Kwon O.S., Lee H.J., Yeon J.E., et al. Improvement of liver function and non-invasive fibrosis markers in hepatitis B virus-associated cirrhosis: 2years of entecavir treatment. J. Gastroenterol. Hepatol. 2015; 30(12): 1775–81. https://doi.org/10.1111/jgh.130208. Marcellin P., Gane E., Buti M., Afdhal N., Sievert W., Jacobson I.M., et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013; 381(9865): 468–75. https://doi.org/10.1016/S0140-6736(12)61425-19. Terrault N.A., Lok A.S.F., McMahon B.J., Chang K.M., Hwang J.P., Jonas M.M., et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018; 67(4): 1560–99. https://doi.org/10.1002/hep.2980010. Yao F.Y., Bass N.M. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection. J. Hepatol. 2000; 33(2): 301–7. https://doi.org/10.1016/s0168-8278(00)80371-211. Lok A.S.F., McMahon B.J. Chronic hepatitis B: update 2009. Hepatology. 2009; 50(3): 661–2. https://doi.org/10.1002/hep.2319012. Ono A., Suzuki F., Kawamura Y., Sezaki H., Hosaka T., Akuta N., et al. Long-term continuous entecavir therapy in nucleos(t)idenaïve chronic hepatitis B patients. J. Hepatol. 2012; 57(3): 508–14. https://doi.org/10.1016/j.jhep.2012.04.03713. Schiff E.R., Lai C.L., Hadziyannis S., Neuhaus P., Terrault N., Colombo M., et al., Adefovir Dipivoxil Study 435 International Investigators Group. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology. 2003; 38(6): 1419–27. https://doi.org/10.1016/j.hep.2003.09.04014. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., Chang T.T., Kitis G., Rizzetto M., et al., Adefovir Dipivoxil 438 Study Group. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology. 2006; 131(6): 1743–51. https://doi.org/10.1053/j.gastro.2006.09.02015. Liaw Y.F., Raptopoulou-Gigi M., Cheinquer H., Sarin S.K., Tanwandee T., Leung N., et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. Hepatology. 2011; 54(1): 91–100. https://doi.org/10.1002/hep.2436116. Shim J.H., Lee H.C., Kim K.M., Lim Y.S., Chung Y.H., Lee Y.S., et al. Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis. J. Hepatol. 2010; 52(2): 176–82. https://doi.org/10.1016/j.jhep.2009.11.00717. Chan H.L., Chen Y.C., Gane E.J., Sarin S.K., Suh D.J., Piratvisuth T., et al. Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naïve patients with HBV-related decompensated cirrhosis. J. Viral. Hepat. 2012; 19(10): 732–43. https://doi.org/10.1111/j.1365-2893.2012.01600.x18. Lee S.K., Song M.J., Kim S.H., Lee B.S., Lee T.H., Kang Y.W., et al. Safety and efficacy of tenofovir in chronic hepatitis B-related decompensated cirrhosis. World J. Gastroenterol. 2017; 23(13): 2396–403. https://doi.org/10.3748/wjg.v23.i13.239619. Köklü S., Tuna Y., Gülşen M.T., Demir M., Köksal A.Ş., Koçkar M.C., et al. Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis. Clin. Gastroenterol. Hepatol. 2013; 11(1): 88–94. https://doi.org/10.1016/j.cgh.2012.10.00320. Lingala S., Ghany M.G. Natural history of hepatitis C. Gastroenterol. Clin. North Am. 2015; 44(4): 717–34. https://doi.org/10.1016/j.gtc.2015.07.00321. European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. J. Hepatol. 2018; 69(2): 461–511. https://doi.org/10.1016/j.jhep.2018.03.02622. Kardashian A.A., Pockros P.J. Novel emerging treatments for hepatitis C infection: a fast-moving pipeline. Therap. Adv. Gastroenterol. 2017; 10(2): 277–82. https://doi.org/10.1177/1756283X1668387523. Miyaki E., Imamura M., Hiraga N., Murakami E., Kawaoka T., Tsuge M., et al. Daclatasvir and asunaprevir treatment improves liver function parameters and reduces liver fibrosis markers in chronic hepatitis C patients. Hepatol. Res. 2016; 46(8): 758–64. https://doi.org/10.1111/hepr.1262124. Rockey D.C., Friedman S.L. Fibrosis Regression After Eradication of Hepatitis C Virus: From Bench to Bedside. Gastroenterology. 2021; 160(5): 1502–20. https://doi.org/10.1053/j.gastro.2020.09.06525. Bachofner J.A., Valli P.V., Kröger A., Bergamin I., Künzler P., Baserga A., et al. Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index. Liver Int. 2017; 37(3): 369–76. https://doi.org/10.1111/liv.1325626. Reddy K.R., Bourlière M., Sulkowski M., Omata M., Zeuzem S., Feld J.J., et al. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis. Hepatology. 2015; 62(1): 79–86. https://doi.org/10.1002/hep.2782627. Fried M., DiBisceglie A., Vierling J.M., Gane E.J., Nevens F., Strasser S.I., et al. TURQUOISE-II: regimens of ABT-450/r/ombitasvir and dasabuvir with ribavirin achieve high SVR12 rates in HCV genotype 1-infected patients with cirrhosis, regardless of baseline characteristics. Hepatology. 2014; 60(Suppl): 1145A. Available at: https://www.natap.org/2014/AASLD/AASLD_03.htm (accessed September 18, 2021).28. Feld J.J., Kowdley K.V., Coakley E., Sigal S., Nelson D.R., Crawford D., et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N. Engl. J. Med. 2014; 370(17): 1594–603. https://doi.org/10.1056/NEJMoa131572229. Lawitz E., Matusow G., DeJesus E., Yoshida E.M., Felizarta F., Ghalib R., et al. Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2). Hepatology. 2016; 64(2): 360–9. https://doi.org/10.1002/hep.2842230. Poordad F., Schiff E.R., Vierling J.M., Landis C., Fontana R.J., Yang R., et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology. 2016; 63(5): 1493–505. https://doi.org/10.1002/hep.2844631. Pol S., Bourliere M., Lucier S., Hezode C., Dorival C., Larrey D., et al., ANRS/AFEF HEPATHER study group. Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients. J. Hepatol. 2017; 66(1): 39–47. https://doi.org/10.1016/j.jhep.2016.08.02132. Sriphoosanaphan S., Thanapirom K., Suksawatamnuay S., Thaimai P., Sittisomwong S., Sonsiri K., et al. Changes in hepatic fibrosis and vitamin D levels after viral hepatitis C eradication using direct-acting antiviral therapy. BMC Gastroenterol. 2020; 20(1): 346. https://doi.org/10.1186/s12876-020-01485-833. Ferenci P., Kozbial K., Mandorfer M., Hofer H. HCV targeting of patients with cirrhosis. J. Hepatol. 2015; 63(4): 1015–22. https://doi.org/10.1016/j.jhep.2015.06.00334. Foster G.R., Pianko S., Brown A., Forton D., Nahass R.G., George J., et al. BOSON Study Group. Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. Gastroenterology. 2015; 149(6): 1462–70. https://doi.org/10.1053/j.gastro.2015.07.04335. Nelson D.R., Cooper J.N., Lalezari J.P., Lawitz E., Pockros P.J., Gitlin N., et al., ALLY-3 Study Team. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015; 61(4): 1127–35. https://doi.org/10.1002/hep.2772636. Gane E.J., Hyland R.H., An D., Svarovskaia E., Pang P.S., Brainard D., et al. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection. Gastroenterology. 2015; 149(6): 1454–61. https://doi.org/10.1053/j.gastro.2015.07.06337. Elsharkawy A., Alem S.A., Fouad R., El Raziky M., El Akel W., Abdo M., et al. Changes in liver stiffness measurements and fibrosis scores following sofosbuvir based treatment regimens without interferon. J. Gastroenterol. Hepatol. 2017; 32(9): 1624–30. https://doi.org/10.1111/jgh.1375838. Afdhal N., Everson G., Calleja J.L., McCaughan G., Symonds W.T., Denning J., et al. Sofosbuvir and ribavirin for the treatment of chronic HCV with cirrhosis and portal hypertension with and without decompensation: early virologic response and safety. J. Hepatol. 2014; 60(Suppl. 1): S28. https://doi.org/10.1016/S0168-8278(14)60070-239. Flamm S.L., Everson G.T., Charlton M., Denning J.M., Arterburn S., Brandt-Sarif T., et al. Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with decompensated cirrhosis: preliminary results of a prospective, multicenter study. Hepatology. 2014; 60(Suppl): 320A. Available at: https://www.natap.org/2014/AASLD/AASLD_36.htm (accessed September 18, 2021).40. Takaoka Y., Miura K., Morimoto N., Ikegami T., Kakizaki S., Sato K., et al., Liver Investigators in the Northern Kanto Study (LINKS) group. Real-world efficacy and safety of 12-week sofosbuvir/velpatasvir treatment for patients with decompensated liver cirrhosis caused by hepatitis C virus infection. Hepatol. Res. 2021; 51(1):51–61. https://doi.org/10.1111/hepr.1357641. Iacobellis A., Siciliano M., Perri F., Annicchiarico B.E., Leandro G., Caruso N., et al. Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study. J. Hepatol. 2007; 46(2): 206–12. https://doi.org/10.1016/j.jhep.2006.08.02042. Ruiz I., Feray C., Pawlotsky J.M., Hézode C. Patient with decompensated hepatitis C virus-related cirrhosis delisted for liver transplantation after successful sofosbuvir-based treatment. Liver Transpl. 2015; 21(3): 408–9. https://doi.org/10.1002/lt.2405143. Gane E.J. The natural history of recurrent hepatitis C and what influences this. Liver Transpl. 2008; 14(Suppl. 2): S36–44. https://doi.org/10.1002/lt.2164644. Garbuzenko D.V., Arefyev N.O. Primary prevention of bleeding from esophageal varices in patients with liver cirrhosis: An update and review of the literature. J. Evid. Based Med. 2020; 13(4): 313–24. https://doi.org/10.1111/jebm.1240745. Manolakopoulos S., Triantos C., Theodoropoulos J., Vlachogiannakos J., Kougioumtzan A., Papatheodoridis G., et al. Antiviral therapy reduces portal pressure in patients with cirrhosis due to HBeAg-negative chronic hepatitis B and significant portal hypertension. J. Hepatol. 2009; 51(3): 468–74. https://doi.org/10.1016/j.jhep.2009.05.03146. Lampertico P., Invernizzi F., Viganò M., Loglio A., Mangia G., Facchetti F., et al. The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: a 12-year prospective cohort study. J. Hepatol. 2015; 63(5): 1118–25. https://doi.org/10.1016/j.jhep.2015.06.00647. Mandorfer M., Kozbial K., Schwabl P., Freissmuth C., Schwarzer R., Stern R. Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. J. Hepatol. 2016; 65(4): 692–9. https://doi.org/10.1016/j.jhep.2016.05.02748. Lens S., Baiges A., Alvarado-Tapias E., LLop E., Martinez J., Fortea J.I., et al. Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension. J. Hepatol. 2020; 73(6): 1415–24. https://doi.org/10.1016/j.jhep.2020.05.05049. Afdhal N., Everson G.T., Calleja J.L., McCaughan G.W., Bosch J., Brainard D.M., et al. Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension. J. Viral. Hepat. 2017; 24(10): 823–31. https://doi.org/10.1111/jvh.1270650. Puigvehí M., Londoño M.C., Torras X., Lorente S., Vergara M., Morillas R.M., et al. Impact of sustained virological response with DAAs on gastroesophageal varices and Baveno criteria in HCV-cirrhotic patients. J. Gastroenterol. 2020; 55(2): 205–16. https://doi.org/10.1007/s00535-019-01619-051. Moon A.M., Green P.K., Rockey D.C., Berry K., Ioannou G.N. Hepatitis C eradication with direct-acting anti-virals reduces the risk of variceal bleeding. Aliment. Pharmacol. Ther. 2020; 51(3): 364–73. https://doi.org/10.1111/apt.15586